Back to top

crispr: Archive

Zacks Equity Research

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

ALLONo Net Change FULCPositive Net Change IMTXPositive Net Change TRDAPositive Net Change